Table 2.
A–C: Estimates of linear mixed-effect models.
| (A) p < 0.1 among Ph1 and Ph2 | Ph1/Ph2 | Time | Interaction | Constant |
|---|---|---|---|---|
| immunoglobulin J chain | 0.9 (−0.09, 1.88), p < 0.1 |
0.002 (−0.13, 0.14) | −0.02 (−0.22, 0.18) | 9.72 (9.06, 10.37), p < 0.01 |
| heparin cofactor 2 | 0.9 (−0.0004, 1.80), p < 0.1 |
−0.09 (−0.27, 0.09) | −0.12 (−0.39, 0.15) | 10.17 (9.57, 10.77), p < 0.01 |
| immunoglobulin lambda-1 light chain isoform X47 | −1.35 (−2.85, 0.16), p < 0.1 |
−0.43 (−1.38, 0.53) | 0.41 (−1.02, 1.84) | 5.37 (4.37, 6.37), p < 0.01 |
| angiotensinogen | 0.88 (−0.14, 1.89), p < 0.1 |
−0.12 (−0.30, 0.06) | −0.16 (−0.43, 0.11) | 10.16 (9.48, 10.84), p < 0.01 |
| hypothetical protein JEQ12_001510 | 0.84 (0.18, 1.50), p < 0.05 |
0.06 (−0.06, 0.17) | −0.11 (−0.28, 0.06) | 11.02 (10.57, 11.46), p < 0.01 |
| (B) p < 0.1 over time | Ph1/Ph2 | Time | Interaction | Constant |
| apolipoprotein C-III | −0.14 (−1.73, 1.46) | −0.48 (−0.79, −0.16), p < 0.01 |
0.17 (−0.31, 0.64) | 9.51 (8.45, 10.58), p < 0.01 |
| ceruloplasmin isoform X2 | 0.09 (−0.78, 0.96) | 0.1 (−0.02, 0.23), p < 0.1 |
0.02 (−0.17, 0.20) | 12.34 (11.76, 12.91), p < 0.01 |
| complement C4-like isoform X1 | 0.01 (−1.06, 1.09) | −0.25 (−0.43, −0.06), p < 0.05 | −0.03 (−0.31, 0.26) | 11.02 (10.31, 11.74), p < 0.01 |
| inter-alpha-trypsin inhibitor heavy chain H2 isoform X2 | 0.61 (−0.14, 1.36) | −0.22 (−0.33, −0.12), p < 0.01 | −0.02 (−0.18, 0.14) | 11.57 (11.07, 12.07), p < 0.01 |
| prothrombin precursor | 0.34 (−1.10, 1.79) | −0.27 (−0.48, −0.05), p < 0.05 | 0.08 (−0.24, 0.40) | 10.98 (10.02, 11.95), p < 0.01 |
| serpin A3–7 isoform X2 | 0.16 (−0.63, 0.95) | 0.19 (0.05, 0.34), p < 0.01 |
−0.1 (−0.32, 0.12) | 10.36 (9.83, 10.88), p < 0.01 |
| serpin A3–8 | 0..35 (−0.84, 1.53) | 0.47 (0.28, 0.65), p < 0.01 |
0.07 (−0.20, 0.35) | 8.86 (8.07, 9.65), p < 0.01 |
| serpin A3–6-like | −1.55 (−4.04, 0.93) | −0.42 (−0.89, 0.05), p < 0.1 |
0.28 (−0.40, 0.95) | 9.63 (7.92, 11.35), p < 0.01 |
| serum amyloid A protein | 0.29 (−1.64, 2.21) | 1.42 (1.06, 1.79), p < 0.01 |
−0.03 (−0.55, 0.49) | 4.09 (2.73, 5.46), p < 0.01 |
| glutathione peroxidase 3 | −0.39 (−1.82, 1.04) | 0.27 (−0.01, 0.55), p < 0.1 |
0.31 (−0.07, 0.70) | 5.69 (4.64, 6.74), p < 0.01 |
| synaptotagmin-like protein 4 isoform X3 | −0.21 (−1.10, 0.69) | 0.18 (0.01, 0.34), p < 0.05 |
−0.01 (−0.26, 0.24) | 16.43 (15.84, 17.03), p < 0.01 |
| serum paraoxonase/arylesterase 1 isoform X1 | 0.35 (−0.38, 1.08) | −0.11 (−0.22, 0.01), p < 0.1 |
−0.1 (−0.27, 0.08) | 11.6 (11.11, 12.08), p < 0.01 |
| transthyretin precursor | −1.35 (−4.77, 2.06) | −0.48 (−0.97, 0.01), p < 0.1 |
0.1 (−0.67, 0.87) | 11.47 (9.21, 13.73), p < 0.01 |
| lumican | 0.2 (−1.22, 1.62) | 0.35 (0.07, 0.62), p < 0.05 |
0.47 (0.06, 0.87), p < 0.05 |
6.57 (5.08, 7.02), p < 0.01 |
| zinc finger protein 264-like isoform X1 | 0.28 (−0.58, 1.14) | 0.17 (−0.01, 0.36), p < 0.1 |
−0.2 (−0.46, 0.06) | 12.15 (11.54, 12.75), p < 0.01 |
| Hemopexin | −0.8 (−2.22, 0.61) | −0.38 (−0.63, −0.14), p < 0.01 |
0.19 (−0.18, 0.55) | 12.93 (11.98, 13.87), p < 0.01 |
| complement C3 | 0.08 (−0.66, 0.82) | −0.12 (−0.25, 0.01), p < 0.1 |
−0.001 (−0.20, 0.20) | 9.53 (9.03, 10.02), p < 0.01 |
| hemoglobin subunit beta | −1.74 (−4.02, 0.53) | 0.44 (0.02, 0.85), p < 0.05 |
0.17 (−0.45, 0.80) | 13.25 (11.74, 14.77), p < 0.01 |
| apolipoprotein A-II | 0.58 (−0.45, 1.61) | −0.18 (−0.38, 0.03), p < 0.1 |
−0.08 (−0.39, 0.23) | 12.09 (11.40, 12.78), p < 0.01 |
| PHD finger protein 21A isoform X13 | −0.05 (−1.18, 1.08) | 0.22 (0.001, 0.44), p < 0.05 |
−0.04 (−0.37, 0.29) | 14.89 (14.13, 15.64), p < 0.01 |
| hypothetical protein JEQ12_002713 | 0.54 (−0.15, 1.22) | −0.11 (−0.24, 0.01), p < 0.1 |
0.03 (−0.16, 0.22) | 12.24 (11.78, 12.69), p < 0.01 |
| hypothetical protein JEQ12_008125 | −0.42 (−1.05, 0.22) | −0.15 (−0.26, −0.04), p < 0.01 |
0.14 (−0.03, 0.31) | 17.7 (17.28, 18.12), p < 0.01 |
| hypothetical protein JEQ12_008126 | 0.4 (−0.19, 1.00) | −0.12 (−0.21, −0.02), p < 0.05 |
0.08 (−0.06, 0.22) | 15.48 (15.09, 15.88), p < 0.01 |
| hypothetical protein JEQ12_008387 | 0.34 (−0.33, 1.01) | 0.53 (0.39, 0.66), p < 0.01 |
−0.05 (−0.25, 0.15) | 10.18 (9.73, 10.62), p < 0.01 |
| hypothetical protein JEQ12_005133 | −0.17 (−1.93, 1.58) | 1.72 (1.39, 2.04), p < 0.01 |
0.02 (−0.49, 0.53) | 3.73 (2.63, 4.83), p < 0.01 |
| hypothetical protein JEQ12_003887 | 0.59 (−0.72, 1.91) | −0.22 (−0.46, 0.02), p < 0.1 |
0.03 (−0.33, 0.38) | 13.07 (12.20, 13.95), p < 0.01 |
| hypothetical protein JEQ12_012143 | −0.51 (−2.55, 1.53) | 0.58 (0.17, 0.99), p < 0.01 |
−0.13 (−0.74, 0.49) | 13.01 (11.65, 14.37), p < 0.01 |
| (C) p < 0.1 for group:time interaction | Ph1/Ph2 | Time | Interaction | Constant |
| lumican | 0.2 (−1.22, 1.62) | 0.35 (0.07, 0.62), p < 0.05 |
0.47 (0.06, 0.87), p < 0.05 |
6.57 (5.08, 7.02), p < 0.01 |
| carbonic anhydrase 2 | −1.36 (−3.16, 0.43) | 0.17 (−0.13, 0.47) | 0.39 (−0.06, 0.83), p < 0.1 | 9.62 (8.41, 10.83), p < 0.01 |
Data are expressed as estimates with 95% confidence interval in brackets.